Peleg Anton Y
Division of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Semin Respir Crit Care Med. 2007 Dec;28(6):662-71. doi: 10.1055/s-2007-996413.
Acinetobacter baumannii is a highly resilient, gram-negative coccobacillus that thrives within the unique and complex ecological setting of an intensive care unit. This evolving pathogen has now surpassed human capacity to create new antimicrobials, and has led physicians into a concerning era for hospital-acquired infections. This review presents the available evidence on the therapeutic strategies for A. baumannii infection, with a particular focus on clinical human data. The utility of existing and older antimicrobials such as sulbactam and the polymyxins are explored, as well as, the potential role of newer agents such as tigecycline. Other important adjunctive strategies such as pharmacodynamic target attainment and infection control implementation are briefly discussed. It is now clear that new antimicrobials with unique mechanisms of action are urgently required to combat the rising trends seen globally with drug-resistant A. baumannii.
鲍曼不动杆菌是一种极具韧性的革兰氏阴性球杆菌，在重症监护病房独特而复杂的生态环境中蓬勃生长。这种不断演变的病原体现已超出人类研发新抗菌药物的能力，使医生们进入了医院获得性感染令人担忧的时代。本综述展示了关于鲍曼不动杆菌感染治疗策略的现有证据，特别关注临床人体数据。探讨了现有和较老的抗菌药物如舒巴坦和多粘菌素的效用，以及新型药物如替加环素的潜在作用。还简要讨论了其他重要的辅助策略，如药效学靶点达成和感染控制措施的实施。现在很清楚，迫切需要具有独特作用机制的新型抗菌药物来应对全球耐药鲍曼不动杆菌不断上升的趋势。
